Newron Pharmaceuticals has reported its FY25 results, ahead of what will be an important year for lead asset evenamide in treatment-resistant schizophrenia (TRS). Key operational milestones include the initiation of both ENIGMA-TRS trials, continued patient enrolment across multiple regions and the
